1. Executive Summary
2. Research Methodology
3. Osteoarthritis
3.1 Overview
3.1.1 Symptoms
3.1.2 Risk Factors
3.2 Stages
3.3 Diagnosis & Treatment
3.3.1 Diagnosis
3.3.2 Treatment
4. Market Analysis
4.1 Market Sizing (Actual & Forecasted)
4.2 Market Share Analysis
4.2.1 Market Share by Drugs
4.2.2 Market Share by Region
5. Market Segmentation by Treatment
5.1 Non-Surgical Treatment
5.1.1 Non-Steroidal Anti-Inflammatory Drugs
5.1.1.1 Market Sizing (Actual & Forecasted)
5.1.2 Corticosteroids
5.1.2.1 Market Sizing (Actual & Forecasted)
5.1.3 Hyaluronic Acid Injections
5.1.3.1 Market Sizing (Actual & Forecasted)
5.1.4 Alternate Therapies
5.1.5 Others
5.2 Surgical Treatment
5.2.1 Overview
5.2.2 Market Sizing (Actual & Forecasted)
6. Regional Analysis
6.1 North America
6.1.1 Market Sizing (Actual & Forecasted)
6.2 Europe
6.2.1 Market Sizing (Actual & Forecasted)
6.3 Asia Pacific
6.3.1 Market Sizing (Actual & Forecasted)
7. Market Dynamics
7.1 Industry Trends & Developments
7.1.1 Stem Cell Treatment for Osteoarthritis
7.1.2 Use of Regenerative Medicine for Treatment
7.1.3 Rise in Demand for MAKOplasty
7.1.4 Disease Modifying Drugs
7.2 Growth Drivers
7.2.1 Rising Geriatric Population
Figure 14: Prevalence of Osteoarthritis by Age & Sex, 2017-18
7.2.2 Prevalence of Osteoarthritis Incidences
7.2.3 Rise in Number of Obese Population
7.2.4 Favorable Reimbursement Policies
7.3 Challenges
7.3.1 Stringent Regulatory Compliance
7.3.2 Side Effects of Treatment Procedures
8. Competitive Landscape
8.1 Financial Analysis
8.2 Products Portfolio
9. Company Profiles
9.1 Anika Therapeutics, Inc
9.2 Zimmer Biomet Holdings, Inc.
9.3 Stryker Corporation
9.4 DePuy Synthes (Johnson & Johnson)